Alimera Sciences, Inc. (ALIM) Tops Q4 EPS by 3c

Alimera Sciences, Inc. (NASDAQ: ALIM) reported Q4 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22).

Sees iluvien EU marketing approval by end of Q1, sees meeting with FDA on iluvien during Q2.

For earnings history and earnings-related data on Alimera Sciences, Inc. (ALIM) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• EXL closes $1 billion credit facility, up from $600 million
• Halozyme adds biotech executive Appelhans to its board